NCT06202313View on ClinicalTrials.gov

Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

February 10, 2024

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2028

Conditions
Triple Negative Breast Cancer
Interventions
BIOLOGICAL

Cadonilimab

Participants receive Cadonilimab 10mg/kg IV on Day 1 of each 21-day cycle PLUS Eribulin 1.4mg/m\^2 IV on Days 1 and 8 of each 21-day cycle.

DRUG

Eribulin

Participants receive Eribulin 1.4mg/m\^2 IV on Days 1 and 8 of each 21-day cycle.

Trial Locations (1)

110004

Shengjing Hospital of China Medical University, Shenyang

All Listed Sponsors
lead

Shengjing Hospital

OTHER